文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

重症多重耐药革兰阴性菌感染7天与14天抗菌治疗比较(OPTIMISE):一项随机、开放标签、非劣效性临床试验

Seven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomised, open-label, non-inferiority clinical trial.
PubMed 文献 · Crit Care · 2024-12-18
一句话结论OPTIMISE试验因招募率低提前终止,未能确定7天较14天抗菌治疗在ICU重症多重耐药革兰阴性菌感染中的非劣效性。

OPTIMISE为随机、多中心、开放标签、平行对照、非劣效性试验,纳入ICU获得性重症多重耐药革兰阴性菌(MDR-GNB)感染、且已接受适当抗菌治疗第7天血流动力学稳定、无发热>48小时的成人患者,1:1随机分为第7(±1)天停药组或继续至总疗程14(±1)天组。主要终点为随机化后28天内临床失败(死亡或感染复发),非劣效标准为7天组与14天组临床失败率差值的双侧95%CI上限在意向治疗(ITT)和符合方案(PP)分析中均低于10%。ITT人群106例(7天组59例、14天组47例),临床失败率7天组42.4% vs 14天组44.7%(风险差-2.3,95%CI -21.3至16.7);PP人群75例(7天组47例、14天组28例),临床失败率7天组46.8% vs 14天组50.0%(风险差-3.2,95%CI -26.6至20.2)。研究因招募率低在达到计划样本量前终止,未能确定7天治疗的非劣效性。

要点

  • OPTIMISE试验因招募率低提前终止,未能确定7天较14天抗菌治疗在ICU重症MDR-GNB感染中的非劣效性。
  • ITT人群106例:7天组临床失败42.4% vs 14天组44.7%,风险差-2.3(95%CI -21.3至16.7),95%CI上限超过预设10%非劣效界值。
  • PP人群75例:7天组临床失败46.8% vs 14天组50.0%,风险差-3.2(95%CI -26.6至20.2),同样未达非劣效标准。
  • 感染部位以呼吸道为主(73/68.9%),病原以碳青霉烯耐药肠杆菌目为主(42/39.6%)。
  • 入组条件为ICU获得性感染、适当抗菌治疗第7天血流动力学稳定且无发热>48小时。

适用人群与场景

  • 成人ICU患者,发生重症多重耐药革兰阴性菌(MDR-GNB)感染,且感染在入住ICU≥48小时后发生。
  • 入组时需在适当抗菌治疗第7天血流动力学稳定且无发热>48小时。

诊断标准与关键阈值

  • 非劣效性标准:7天组与14天组临床失败率差值的双侧95%CI上限在ITT和PP分析中均低于10%。
  • 临床失败定义:随机化后28天内死亡或感染复发。

处置流程与药物剂量

  • 第7(±1)天停用抗菌治疗(7天组)或继续至总疗程14(±1)天(14天组),1:1随机分配。

研究设计与关键结果

  • 研究类型:随机、多中心、开放标签、平行对照、非劣效性临床试验;因招募率低在达到计划样本量前终止。
  • ITT人群106例(7天组59例、14天组47例):临床失败率7天组42.4% vs 14天组44.7%,风险差-2.3(95%CI -21.3至16.7)。
  • PP人群75例(7天组47例、14天组28例):临床失败率7天组46.8% vs 14天组50.0%,风险差-3.2(95%CI -26.6至20.2)。
  • 感染部位以呼吸道为主(73/68.9%),病原以碳青霉烯耐药肠杆菌目为主(42/39.6%)。

证据类型、等级与局限

  • 证据类型:随机、多中心、开放标签、平行对照、非劣效性临床试验(OPTIMISE,NCT05210387)。
  • 局限:研究因招募率低在达到计划样本量前提前终止,未能确定非劣效性。

对床旁实践的改变

  • 作者结论:由于招募率低导致早期终止,OPTIMISE试验未能确定7天较14天抗菌治疗在重症MDR-GNB感染中的非劣效性。

指南或共识出处

  • OPTIMISE试验(NCT05210387),发表于Crit Care。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Shorter courses of antimicrobial therapy have been shown to be non-inferior to longer durations for the management of several infections. However, data on critically ill patients with severe infections by multidrug-resistant Gram-negative bacteria (MDR-GNB) are scarce. In the duratiOn of theraPy in severe infecTIons by MultIdrug-reSistant gram-nEgative bacteria (OPTIMISE) trial, we assessed the non-inferiority of 7-day versus 14-day antimicrobial therapy for patients with intensive care unit (ICU)-acquired severe infections by MDR-GNB.

METHODS: This was a randomised multicenter, open-label, parallel controlled, non-inferiority trial. Adult patients with severe infections by MDR-GNB initiated ≥ 48 h of ICU admission were eligible if they were hemodynamically stable and without fever > 48 h on the 7th day of appropriate antimicrobial therapy. Patients were 1:1 randomised to discontinue antimicrobial therapy on the 7th (± 1) day or to continue for a total of 14 (± 1) days. The primary outcome was clinical failure, defined as death or relapse of infection within 28 days of randomisation. An upper edge of the two-tailed 95% confidence interval (CI) of the delta between the clinical failure rate in the 7- and the 14-day lower than 10% in both intention-to-treat (ITT) and per protocol (PP) analyses was set as the non-inferiority criteria.

RESULTS: A total of 106 patients composed the ITT population: 59 and 47 allocated to 7- and 14-day groups, respectively. The PP population included 75 patients: 47 and 28 in the 7- and 14-day groups, respectively. Clinical failure occurred in 42.4% and 44.7% of the ITT population in 7- and 14-day groups, respectively, (risk difference (RD) - 2.3, 95%CI - 21.3 to 16.7), and in 46.8% and 50.0% of the PP population in 7- and 14-day groups, respectively (RD - 3.2, 95%CI - 26.6 to 20.2). Most infections were of the respiratory tract (73/68.9%) and caused by carbapenem-resistant Enterobacterales (42/39.6%). The study was interrupted before reaching planned sample size due to low recruitment rate.

CONCLUSION: The OPTIMISE trial could not determine the non-inferiority of 7-day compared to 14-day therapy for severe infections caused by MDR-GNB due to early termination related to the low recruitment rate.

TRIAL REGISTRATION: NCT05210387 on January 13, 2022.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Arns B, Kalil AC, Sorio GGL, et al. Seven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomised, open-label, non-inferiority clinical trial. Crit Care. 2024. PMID: 39695798. doi:10.1186/s13054-024-05178-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。